RxDoctor Payments Data

Kevin Ergle, MD

Interventional Cardiology · Plantation, FLNPI 1982964870

Payments from drug & device makers

$34,448in general payments, 2019–2025

Across 569 payments — averaging $60.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$15K
  • Abbott$7K
  • Edwards Lifesciences$4K
  • Angiodynamics, Inc.$1K
  • Boston Scientific$1K
  • Cardiva Medical, Inc.$1K
  • plus $5K from 34 others

What the payments were for

  • Consulting fees$2,1186%
  • Speaking & faculty fees$3,61310%
  • Travel & lodging$7,41922%
  • Food & beverage$21,28462%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,448 in reported general payments places this provider in the 70th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$283,175
Medicare patients
812
Services billed
2,857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban309$369,147
XareltoRivaroxaban97$119,345
EntrestoSacubitril/Valsartan72$103,618
JardianceEmpagliflozin71$102,389
BrilintaTicagrelor68$63,762
FarxigaDapagliflozin Propanediol22$29,724
MultaqDronedarone Hcl16$14,254
Repatha SureclickEvolocumab13$13,521
Prasugrel Hcl58$10,644
Atorvastatin Calcium544$6,047
Rosuvastatin Calcium303$3,932
Nifedipine ErNifedipine105$3,154
Metoprolol Succinate242$3,060
ClopidogrelClopidogrel Bisulfate284$2,816
Bumetanide51$2,176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$226$369,147309 claims
Johnson & JohnsonXarelto$175$119,34597 claims
NovartisEntresto$290$103,61872 claims
Boehringer IngelheimJardiance$393$102,38971 claims
AstraZenecaBrilinta, Farxiga$207$93,48690 claims
Sanofi-aventis U.S. LLCMultaq$18$14,25416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Plantation

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →